Lyell Immunopharma (LYEL) Analyst & Key Data

Analyst Consensus

Buy6 analysts

Buy

Updated Sep 12, 2026

Total Analysts6

Buy

3

Hold

3

Sell

1

Ratings

Updated Sep 12, 2026

Overall Rating

C+

DCF Score3.0 / 5

Debt / Equity Score3.0 / 5

Price / Book Score4.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$11.96

Median Target+230.27%

$39.50

Potential upside vs current price

DCF Value-97.01%

$0.36

Potential downside vs current price

Current Stock Price

$11.96

Median Target+230.27%

$39.50

Potential upside vs current price

DCF Value-97.01%

$0.36

Potential downside vs current price

Analyst Consensus

Buy6 analysts

Buy

Updated Sep 12, 2026

Total Analysts6

Buy

3

Hold

3

Sell

1

Ratings

Updated Sep 12, 2026

Overall Rating

C+

DCF Score3.0 / 5

Debt / Equity Score3.0 / 5

Price / Book Score4.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$11.96

Median Target+230.27%

$39.50

Potential upside vs current price

DCF Value-97.01%

$0.36

Potential downside vs current price

Current Stock Price

$11.96

Median Target+230.27%

$39.50

Potential upside vs current price

DCF Value-97.01%

$0.36

Potential downside vs current price

Lyell Immunopharma, Inc.